Seres Therapeutics (MCRB) Tops Q3 EPS by 24c, Beats on Revenues

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.17), $0.24 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $23 million versus the consensus estimate of $16 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• H.C. Wainwright Starts Seres Therapeutics (MCRB) at Buy
• H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat